Brainstorm seeks accelerated approval for NurOwn treatment from the FDA.
1 report, 0 independent
Updated Jul 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Brainstorm seeks accelerated approval for NurOwn treatment from the FDA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Brainstorm
company in Madrid, Spain
Nothing else this week.
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Inventiva seeks FDA approval for lanifibranor in the U.S. market.
- FDA communicated eligibility for accelerated approval for ProKidney Corp., which plans to present study results at ASN.
- FDA granted approval for the FAYUVI treatment on October 7, 2026.
- Research advances have led to the approval of new therapies by the FDA.
Coverage
Newest first; wire copies grouped- Unknown outlet